Pfizer breaks ground on new $200 million biologics facility
Pfizer (NYSE: PFE) has broken ground on a new $200 million biologics clinical manufacturing facility in Andover, Massachusetts.
This expansion will create a 175,000 square foot state-of-the-art facility with the capacity to produce high quality, complex biologics and vaccines. 75 new employees will be hired to support clinical manufacturing. In addition to the Andover site, Pfizer’s research and development hub is also located in Massachusetts, in Cambridge.
The new site is set to be operational by January 2019.
John Ludwig, senior VP at Pfizer, says: “The expansion of Pfizer’s presence in Andover will provide state-of-the-art manufacturing to help bring new medicines and vaccines to the patients we serve. Andover is a crucial part of our global footprint for both clinical and commercial manufacturing, and we believe it provides an attractive location for growth in the coming years.”
Local senator, Barbara L’Italien, comments: “This five-story building will add 75 new permanent manufacturing jobs and 200 temporary construction jobs to Pfizer’s Andover campus, already home to 1,200 employees. This project is a testament to Pfizer’s commitment to Andover and I look forward to the facility opening in early 2019.”
Pfizer has announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee …
Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their …